20 abr 2017 año - FDA announced the restricted the use of codeine and tramadol medicines in children. On April 20, the FDA approved RoxyBond (oxycodone hydrochloride), an opioid analgesic indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. RoxyBond is the first immediate-release opioid analgesic approved with labeling describing its abuse-deterrent properties consistent with the FDA’s 2015 Guidance for Industry: Abuse- Deterrent Opio
Añadido al timeline:
fecha:
20 abr 2017 año
Ahora mismo
~ 8 years and 6 months ago